Novartis (NYSE:NVS)‘s stock had its “neutral” rating restated by equities researchers at JPMorgan Chase & Co. in a research note issued on Thursday.

Other analysts have also issued research reports about the stock. Nord/LB reiterated a “neutral” rating on shares of Novartis in a research note on Tuesday, January 2nd. Bank of America downgraded shares of Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Monday. Leerink Swann raised their price target on shares of Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Finally, Zacks Investment Research downgraded shares of Novartis from a “buy” rating to a “hold” rating in a research report on Friday, October 6th. Five investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating to the company. Novartis has a consensus rating of “Hold” and an average target price of $85.32.

Shares of Novartis (NVS) opened at $86.88 on Thursday. The stock has a market cap of $227,480.00, a P/E ratio of 30.92, a PEG ratio of 2.32 and a beta of 0.74. Novartis has a 12 month low of $69.53 and a 12 month high of $87.29. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.04. The company had revenue of $12.41 billion for the quarter, compared to analyst estimates of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The business’s quarterly revenue was up 2.4% on a year-over-year basis. During the same quarter last year, the firm posted $1.23 earnings per share. sell-side analysts forecast that Novartis will post 4.79 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in NVS. Berkshire Asset Management LLC PA boosted its holdings in Novartis by 56.6% in the fourth quarter. Berkshire Asset Management LLC PA now owns 4,511 shares of the company’s stock worth $379,000 after purchasing an additional 1,630 shares during the period. Benjamin F. Edwards & Company Inc. boosted its holdings in Novartis by 4.0% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 22,734 shares of the company’s stock worth $1,909,000 after purchasing an additional 868 shares during the period. DAVENPORT & Co LLC boosted its holdings in Novartis by 76.2% in the fourth quarter. DAVENPORT & Co LLC now owns 12,175 shares of the company’s stock worth $1,022,000 after purchasing an additional 5,265 shares during the period. Koshinski Asset Management Inc. acquired a new position in Novartis in the fourth quarter worth $210,000. Finally, Creative Planning boosted its holdings in Novartis by 1.5% in the fourth quarter. Creative Planning now owns 59,777 shares of the company’s stock worth $5,019,000 after purchasing an additional 887 shares during the period. 10.85% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2018/01/18/jpmorgan-chase-co-reiterates-neutral-rating-for-novartis-nvs.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.